Equities Research Analysts’ Updated EPS Estimates for August, 23rd (MYGN, NKE, OTB, PTEC, SPPJY, TAC, TECD, TIGO, TKC, TLRA)

Equities Research Analysts’ updated eps estimates for Friday, August 23rd:

Myriad Genetics (NASDAQ:MYGN) had its sell rating reiterated by analysts at Barclays PLC. Barclays PLC currently has a $22.00 price target on the stock.

Nike (NYSE:NKE) had its buy rating reissued by analysts at Guggenheim. They currently have a $100.00 price target on the stock.

On The Beach Group (LON:OTB) had its buy rating reissued by analysts at Jefferies Financial Group Inc. They currently have a GBX 545 ($7.12) target price on the stock.

Playtech (LON:PTEC) had its buy rating reaffirmed by analysts at Shore Capital.

Sappi (OTCMKTS:SPPJY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “SAPPI LTD -ADR is the world ‘s leading producer of coated fine paper. They hold major market shares in Europe, North America and Africa. They have customers in over 100 countries worldwide. Their manufacturing operations span eight countries on three continents. “

TransAlta (NYSE:TAC) (TSE:TA) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “TransAlta is Canada’s largest non-regulated electric generation and marketing company. “

Tech Data (NASDAQ:TECD) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. Zacks Investment Research currently has $95.00 price target on the stock. According to Zacks, “Shares of Tech Data have increased so far in the year, owing to its third straight quarter of earnings beat in first-quarter fiscal 2020. The company’s bottom line also registered double-digit growth year over year, backed by lower costs of products sold and reduced operating expenses. Going ahead, management issued a robust bottom-line view for second-quarter fiscal 2020. Tech Data is working toward being a more flexible and cost-effective organization with the Global Business Optimization Program. The increasing demand for data center systems, cloud and mobility products also bodes well. However, the top line missed the consensus mark and declined year over year due to sluggishness in the Europe region. This led to a dismal fiscal sales projection. Also, intense competition and headwinds related to data security act as deterrents.”

Millicom International Cellular (NASDAQ:TIGO) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “MILLICOM INTL is a leading international operator of cellular telephony services, primarily in emerging markets where the basic telephone service is often inadequate and where economic development and change are creating new demand for communication services. MIC has sought to establish an early presence in markets with little or no cellular service by applying for cellular licenses, primarily through joint ventures with prominent local business partners. “

Turkcell Iletisim Hizmetleri A.S. (NYSE:TKC) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Turkcell is the leading provider of mobile communications services in Turkey. “

Telaria (NYSE:TLRA) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Telaria provides a software-based platform to manage video advertising. The company provides publishers with real-time analytics and decision making tools to control their video advertising business. The company changed its name from Tremor Video to Telaria in 2017. “

Tocagen (NASDAQ:TOCA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $5.25 price target on the stock. According to Zacks, “Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company’s lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. “

Receive News & Ratings for Myriad Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.